|
|
Switchable magneto-plasmonic contrast agents and molecular imaging technologies | |
| |
SWIMMOT will establish the scientific and technological basis for a radically new technique for in vivo molecular imaging based on a switchable contrast agent (CA) and corresponding optical imaging technology. Our CA will be based on novel magnetic core / plasmonic gold shell nanorods with specifically engineered biofunctional shells. We will develop a new magneto-plasmonic imaging technique based on magnetic excitation and plasmonic signal
generation to realise multimodal optical coherence tomography / photoacoustic imaging modes. The magneto-plasmonic imaging technique will turn our CA on and off, which will allow complete removal of the imaging background. This discrimination of the background from the CA signal will yield ultra-high contrast molecular imaging. In addition, SWIMMOT, for the first time, will enable in vivo quantification of soluble biomarker concentrations and visualisation down to cellular resolution, which holds the potential to revolutionise molecular
imaging and to surpass all current technological paradigms.
|